Optimizing LDL-C control with nonstatin oral therapy in high CV risk patients
22 May 2025
byDr. Carlos Escobar Cervantes, La Paz University Hospital, Spain; Prof. Ioanna Gouni- Berthold, University of Cologne, Germany
Inadequate control of cardiovascular (CV) risk factors, particularly hypercholesterolaemia, continues to drive high global mortality rates from CV disease (CVD). At a recent industry-sponsored meeting, Dr Carlos Escobar Cervantes from La Paz University Hospital, Spain, discussed major barriers to achieving optimal LDL-cholesterol (LDL-C) control, while Professor Ioanna Gouni-Berthold from the University of Cologne, Germany, shared insights and real-world evidence on CV risk reduction with bempedoic acid.
